Repros Names Larry Dillaha, M.D., its Permanent President and CEO
April 10 2017 - 9:18AM
Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that the
Company’s Board of Directors has appointed Larry Dillaha, M.D., the
President and Chief Executive Officer of the Company, effective
immediately. Dr. Dillaha has been serving in these capacities
on an interim basis since February 1, 2017. Dr. Dillaha has
also been named to the Board, filling an existing vacancy.
“Larry is the right person to lead Repros forward as we advance
our pipeline and move toward our next stage of growth,” said
Patrick Fourteau, Chairman of the Company’s Board. “We are
confident that Larry’s fresh perspective, extensive experience and
enthusiasm for Repros’ future will be of great value as we face our
near-term challenges and set a course for the longer term
future.”
Dr. Dillaha was previously the Chief Executive Officer of
CavtheRx, an inception stage biotechnology company, and before that
the Chief Operating Officer and Chief Medical Officer of New Haven
Pharmaceuticals, a specialty pharmaceutical company. He also served
as Chief Medical Officer of Insys Therapeutics, Sciele Pharma and
as Medical Director of Sanofi-Sythelabo. Dr. Dillaha received an
M.D. degree from the University of Tennessee, Memphis.
About Repros Therapeutics
Inc.®
Repros Therapeutics focuses on the development
of small molecule drugs for major unmet medical needs that treat
male and female reproductive disorders.
Forward-Looking Statements
Any statements made by the Company that are not
historical facts contained in this release are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and are subject to various risks, uncertainties
and other factors that could cause the Company’s actual results,
performance or achievements to differ materially from those
expressed or implied by such forward-looking statements. These
statements often include words such as “may,” “will,” “expect,”
“anticipate,” “continue,” “estimate,” “project,” “intend,”
“believe,” “plan,” “seek,” “could,” “can,” “should” or similar
expressions. These statements are based on assumptions that the
Company has made in light of the Company’s experience in the
industry, as well as the Company’s perceptions of historical
trends, current conditions, expected future developments and other
factors the Company believes are appropriate in these
circumstances. Forward-looking statements include, but are not
limited to, those relating to the Company’s pipeline and plans for
growth, and are subject to such risks as are identified in the
Company’s most recent Annual Report on Form 10-K and in any
subsequent quarterly reports on Form 10-Q. These documents are
available on request from Repros Therapeutics or at www.sec.gov.
Repros disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
For more information, please visit the Company’s
website at http://www.reprosrx.com.
CONTACT:
Investor Relations:
Thomas Hoffmann
The Trout Group
(646) 378-2931
thoffmann@troutgroup.com
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Royalty Pharma (NASDAQ:RPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024